Advanced or recurrent gastric cancer
Conditions
Interventions
Sponsors
Yamaguchi University Graduate School of Medicine, Digestive surgery and surgical oncology
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Advanced or recurrent gastric cancer and resistant for standard therapy. 2. Performance status 0-2 (ECOG) 3. No need of evaluable tumor lesion 4. No major surgery, radiotherapy, or chemotherapy within 4 weeks prior to the study 5. predicted life expectancy of at least 3 months 6. Adequate baseline organ functions, defined as a leukocyte count of at least 2000, platelet count of at least 75000, and aspartate aminotransferase and alanine aminotransferase levels three times or less than the upper limit of the institutional reference range; and serum creatinine below 2.0 mg⁄ dL. 7. with HLA-A2402 8. Written informed consent.
Exclusion criteria
Exclusion criteria: Serious infectious disease or other severe complications (e.g. pulmonary fibrosis / interstitial pneumonia, uncontrollable diabetes); pregnancy or lactation, or trying to get pregnant; a history of drug allergy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Safety | — |
Secondary
| Measure | Time frame |
|---|---|
| Immunological effect Objective responses Overall survival | — |
Countries
Japan
Contacts
Public ContactShigefumi Yoshino
Yamaguchi University Graduate School of Medicine Digestive surgery and surgical oncology
Outcome results
None listed